Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Suresh Ratnam

Texas Oncology-McAllen

Dr. Ratnam received his professional medical degree from Kasturba Medical College, Karnataka, India in 1990. He completed an internship at St. Joseph Mercy Hospital in Pontiac, Michigan in 1991; an internal medicine residency at University Health Center, Detroit, Michigan in 1994; and a medical oncology fellowship at the National Cancer Institute, Bethesda, Maryland in 1996. Dr. Ratnam received his B.S. degree from Cambridge University in Cambridge, England, in 1982.